Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Alemtuzumab Versus Anti-Thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
This study is currently recruiting participants.
Study NCT00331162   Information provided by Wake Forest University Baptist Medical Center
First Received: May 26, 2006   Last Updated: December 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Graft Rejection
Interventions listed in this trial
Alemtuzumab
Anti-Thymocyte Globulin
Additional drug interventions recognized in this trial
Antilymphocyte Serum
Pancrelipase
More general drug interventions related to this trial
Antineoplastic Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Wake Forest University Baptist Medical Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services